| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 16 | +56.25% | -0.57% | +1.36% | -1.93% | -1.30% | — |
| 14d | 16 | +43.75% | -2.08% | +1.85% | -3.93% | -1.82% | — |
| 30d | 16 | +46.67% | -0.96% | +3.26% | -4.23% | -4.21% | — |
| 60d | 16 | +37.50% | +6.62% | +1.10% | +6.16% | +0.78% | — |
| 90d | 16(1 pending) | +46.67% | +8.86% | +4.79% | +4.07% | +1.18% | — |
| 180d | 16(5 pending) | +9.09% | +40.95% | +10.60% | +30.35% | +27.88% | — |
| 1y | 16(5 pending) | +0.00% | +61.44% | +18.79% | +42.64% | +13.51% | — |
| 2y | 16(11 pending) | +0.00% | +222.53% | +38.04% | +184.49% | +165.94% | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 1,750 | $105.47 | $184.6K | 59,003 | Apr 20, 2026 | Apr 21, 2026 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 5,265 | — | — | 13,282 | Mar 26, 2026 | Mar 27, 2026 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | PURCHASE Chief Financial Officer | 19,500 | $19.19 | $374.2K | 80,253 | Mar 26, 2026 | Mar 27, 2026 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 24,765 | $104.24 | $2.58M | 60,753 | Mar 26, 2026 | Mar 27, 2026 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 19,500 | — | — | 31,300 | Mar 26, 2026 | Mar 27, 2026 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | PURCHASE Chief Financial Officer | 5,265 | $12.17 | $64.1K | 85,518 | Mar 26, 2026 | Mar 27, 2026 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 16,000 | — | — | 50,800 | Jan 27, 2026 | Jan 27, 2026 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | PURCHASE Chief Financial Officer | 12,000 | $12.17 | $146.0K | 106,523 | Jan 27, 2026 | Jan 27, 2026 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 28,000 | $83.13 | $2.33M | 78,523 | Jan 27, 2026 | Jan 27, 2026 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | PURCHASE Chief Financial Officer | 16,000 | $19.19 | $307.0K | 94,523 | Jan 27, 2026 | Jan 27, 2026 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 12,000 | — | — | 18,547 | Jan 27, 2026 | Jan 27, 2026 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 18,203 | $83.14 | $1.51M | 60,320 | Jan 27, 2026 | Jan 27, 2026 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 8,588 | $82.48 | $708.3K | 78,077 | Jan 20, 2026 | Jan 21, 2026 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | PURCHASEGRANT Stock grant | 25,600 | — | — | 86,665 | Jan 2, 2026 | Jan 6, 2026 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | PURCHASEGRANT Stock grant | 32,000 | — | — | 32,000 | Jan 2, 2026 | Jan 6, 2026 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 1,756 | $46.00 | $80.8K | 61,065 | Apr 22, 2025 | Apr 23, 2025 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 24,903 | $58.73 | $1.46M | 62,821 | Mar 12, 2025 | Mar 14, 2025 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 15,203 | — | — | 30,547 | Mar 12, 2025 | Mar 14, 2025 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 9,700 | — | — | 66,800 | Mar 12, 2025 | Mar 14, 2025 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | PURCHASE Chief Financial Officer | 9,700 | $19.19 | $186.1K | 87,724 | Mar 12, 2025 | Mar 14, 2025 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | PURCHASE Chief Financial Officer | 15,203 | $12.17 | $185.0K | 78,024 | Mar 12, 2025 | Mar 14, 2025 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 2,601 | — | — | 62,821 | Jan 16, 2025 | Jan 17, 2025 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 1,317 | — | — | 65,422 | Jan 16, 2025 | Jan 17, 2025 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | PURCHASEGRANT Stock grant | 31,779 | — | — | 66,739 | Jan 2, 2025 | Jan 6, 2025 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | PURCHASEGRANT Stock grant | 38,520 | — | — | 38,520 | Jan 2, 2025 | Jan 6, 2025 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 6,000 | — | — | 76,500 | Sep 11, 2024 | Sep 13, 2024 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 6,000 | — | — | 45,750 | Sep 11, 2024 | Sep 13, 2024 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 2,203 | $44.59 | $98.2K | 34,960 | Sep 11, 2024 | Sep 13, 2024 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | PURCHASE Chief Financial Officer | 6,000 | $19.19 | $115.1K | 40,960 | Sep 11, 2024 | Sep 13, 2024 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | PURCHASE Chief Financial Officer | 6,000 | $12.17 | $73.0K | 46,960 | Sep 11, 2024 | Sep 13, 2024 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 12,000 | $44.47 | $533.6K | 34,960 | Sep 11, 2024 | Sep 13, 2024 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 1,234 | $25.11 | $31.0K | 37,163 | Apr 18, 2024 | Apr 19, 2024 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 12,000 | — | — | 51,750 | Mar 1, 2024 | Mar 1, 2024 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | PURCHASE Chief Financial Officer | 12,000 | $12.17 | $146.0K | 52,645 | Mar 1, 2024 | Mar 1, 2024 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 12,000 | $32.22 | $386.6K | 40,645 | Mar 1, 2024 | Mar 1, 2024 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 2,248 | $32.33 | $72.7K | 38,397 | Mar 1, 2024 | Mar 1, 2024 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 7,850 | $30.61 | $240.3K | 42,734 | Feb 29, 2024 | Mar 1, 2024 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 2,089 | $31.00 | $64.8K | 40,645 | Feb 29, 2024 | Mar 1, 2024 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 1,452 | $24.63 | $35.8K | 50,584 | Jan 16, 2024 | Jan 18, 2024 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | PURCHASEGRANT Stock grant | 21,000 | — | — | 52,036 | Jan 2, 2024 | Jan 4, 2024 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | PURCHASEGRANT Stock grant | 78,000 | — | — | 78,000 | Jan 2, 2024 | Jan 4, 2024 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | PURCHASEGRANT Stock grant | 12,000 | — | — | 35,186 | May 31, 2023 | Jun 2, 2023 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 4,150 | $26.07 | $108.2K | 31,036 | May 31, 2023 | Jun 2, 2023 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | SALE Chief Financial Officer | 1,189 | $23.21 | $27.6K | 23,186 | Apr 18, 2023 | Apr 19, 2023 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | PURCHASEGRANT Stock grant | 10,625 | — | — | 24,375 | Jan 16, 2023 | Jan 18, 2023 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | PURCHASEGRANT Stock grant | 63,750 | — | — | 63,750 | Jan 16, 2023 | Jan 18, 2023 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | PURCHASEGRANT Stock grant | 82,500 | — | — | 82,500 | Apr 18, 2022 | Apr 19, 2022 ↗ | View → |
| PTGX PROTAGONIST THERAPEUTICS, INC | PURCHASEGRANT Stock grant | 13,750 | — | — | 13,750 | Apr 18, 2022 | Apr 19, 2022 ↗ | View → |